Literature DB >> 21397339

Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study.

Sanna Hagman1, Minna Raunio, Maija Rossi, Prasun Dastidar, Irina Elovaara.   

Abstract

To identify biomarkers of disease activity and progression in multiple sclerosis (MS), we analyzed the serum profiles of cytokines, chemokines and apoptotic molecules in different subtypes of MS including clinically isolated syndrome (CIS) and correlated their levels with clinical and volumetric MRI findings obtained over a one-year follow up. Upregulated levels of apoptotic sFas molecule were found in MS patients with a worsening EDSS score and an accumulation of hypointense lesions in MRI. In such patients, the levels of MIF appeared to be higher than in non-progressing patients. In addition, increased levels of serum TNF-α and CCL2 were found especially in primary progressive MS (PPMS). These observations suggest that serum Fas and MIF are candidate biomarkers of neurological worsening related to progressive neurodegeneration, while serum TNF-α and CCL2 reflect the presence of inflammatory responses in PPMS.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397339     DOI: 10.1016/j.jneuroim.2011.02.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

Review 1.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 2.  Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis.

Authors:  Debora Giunti; Benedetta Parodi; Christian Cordano; Antonio Uccelli; Nicole Kerlero de Rosbo
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

3.  Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.

Authors:  Amanda Ellis; Julie Wieseler; Jacob Favret; Kirk W Johnson; Kenner C Rice; Steven F Maier; Scott Falci; Linda R Watkins
Journal:  J Pain       Date:  2014-01-09       Impact factor: 5.820

Review 4.  Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.

Authors:  Carol Chase Huizar; Itay Raphael; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2020-09-20       Impact factor: 4.868

5.  MIF and D-DT are potential disease severity modifiers in male MS subjects.

Authors:  Gil Benedek; Roberto Meza-Romero; Kelley Jordan; Ying Zhang; Ha Nguyen; Gail Kent; Jia Li; Edwin Siu; Jenny Frazer; Marta Piecychna; Xin Du; Antoine Sreih; Lin Leng; Jack Wiedrick; Stacy J Caillier; Halina Offner; Jorge R Oksenberg; Vijayshree Yadav; Dennis Bourdette; Richard Bucala; Arthur A Vandenbark
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

6.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Robin Conwit; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robert T Naismith; Akshata Ashokkumar; Janel Barnes; Dixie Ecklund; Elizabeth Klingner; Maxine Koepp; Jeffrey D Long; Sneha Natarajan; Brenda Thornell; Jon Yankey; Robert A Bermel; Josef P Debbins; Xuemei Huang; Patricia Jagodnik; Mark J Lowe; Kunio Nakamura; Sridar Narayanan; Ken E Sakaie; Bhaskar Thoomukuntla; Xiaopeng Zhou; Stephen Krieger; Enrique Alvarez; Michelle Apperson; Khurram Bashir; Bruce A Cohen; Patricia K Coyle; Silvia Delgado; L Dana Dewitt; Angela Flores; Barbara S Giesser; Myla D Goldman; Burk Jubelt; Neil Lava; Sharon G Lynch; Harold Moses; Daniel Ontaneda; Jai S Perumal; Michael Racke; Pavle Repovic; Claire S Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Guttman; Vijayshree Yadav; Aram Zabeti
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

Review 7.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

8.  The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines.

Authors:  Kannika Permpoonputtana; Piyarat Govitrapong
Journal:  Neurotox Res       Date:  2012-08-18       Impact factor: 3.911

9.  EBV and vitamin D status in relapsing-remitting multiple sclerosis patients with a unique cytokine signature.

Authors:  Ahmad Nejati; Zabihollah Shoja; Shohreh Shahmahmoodi; Abbas Tafakhori; Yaghoub Mollaei-Kandelous; Farhad Rezaei; Kabir Magaji Hamid; Abbas Mirshafiey; Rozita Doosti; Mohammad Ali Sahraian; Mahmood Mahmoudi; Fazel Shokri; Vince Emery; Sayed Mahdi Marashi
Journal:  Med Microbiol Immunol       Date:  2015-09-13       Impact factor: 3.402

Review 10.  The prognostic utility of MRI in clinically isolated syndrome: a literature review.

Authors:  C Odenthal; A Coulthard
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-15       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.